Introduction {#Sec1}
============

Routine infarct artery stenting and abciximab as adjunctive therapy is currently considered the preferred treatment for patients with ST-segment elevation myocardial infarction (STEMI) \[[@CR1]\], notwithstanding the increased risk of bleeding complications due to the associated anticoagulation state produced by heparin. Post-procedure heparin infusion was used in all the five concluded randomized trials \[[@CR2]--[@CR6]\] of primary percutaneous coronary intervention (PCI) comparing abciximab with placebo, and after the EPIC trial \[[@CR7]\] that showed an excess in bleeding in patients receiving abciximab and heparin, in the other trials the dosage of heparin infusion was lowered with subsequent bleeding rate similar to the one of patients receiving heparin alone without any decreased benefit in terms of ischemic complications. We hypothesized that the maintenance of an anticoagulation state by heparin after PCI is a major determinant of bleeding complications while has only limited impact on the prevention of post-PCI ischemic complications. Thus, we assessed the safety and efficacy of immediate reversal of anticoagulation by protamine after PCI followed by abciximab 12-h infusion without associated heparin infusion.

Methods {#Sec2}
=======

Study population {#Sec3}
----------------

From January 2004 to June 2005 a strategy of routine reversal of anticoagulation state by protamine at the end of primary PCI followed by 12-h abciximab infusion without adjunctive heparin infusion was adopted. During this period a total of 310 patients underwent primary stenting with abciximab administration. The clinical outcome of these patients was compared with the one of a control group of 305 patients treated in the previous 18 months with standard heparin anticoagulation (bolus during PCI in order to achieve an activated coagulation time of 250--300 s followed by 12 h infusion during abciximab infusion (Group 2). Ninety-six patients (56 in the Group 1 and 40 in the Group 2) who required intra-aortic pump implantation during or after PCI or with suboptimal procedural success (TIMI \< 3 or residual stenosis \>50%) were excluded from the analysis because of established need of heparin infusion. Thus our final population is represented by 254 patients in Group 1 and 265 patients in Group 2.

Criteria for primary PCI and infarct artery stenting with adjunctive abciximab therapy were: (1) chest pain persisting more than 30 min associated with ST-segment elevation of at least 0.1 mV in 2 or more contiguous electrocardiographic leads, (2) admission within 12 h of symptom, and (3) reference infarct artery diameter ≥2.5 mm on visual assessment or smaller vessels with non-optimal result after balloon angioplasty. Contraindications for abciximab therapy were: previous fibrinolytic therapy, history of bleeding diathesis or allergy to the study drugs, major surgery within 15 days, active bleeding.

Treatments {#Sec4}
----------

Before catheterization patients received 325 mg of aspirin orally, or 250 mg intravenously. Abciximab (ReoPro, Centocor, Malvern, PA) was administered immediately before the procedure as a bolus of 0.25 mg/kg of body weight followed by a 12-h infusion at a rate of 0.125 μg/kg/min. Heparin was given as an initial bolus of 70 UI/kg, and additional boluses were administered during the procedure to achieve an activated clotting time of 250--300 s. Group 1 patients had reversal anticoagulation state (defined as activated clotting time \<150 s) by the administration of 25--50 mg of protamine at the end of the procedure, while Group 2 patients continued low dose heparin infusion (7 UI/kg/h) for 12 h. Both groups had sheath removal (femoral approach) at the end of the procedure, and hemostasis was achieved by the use of closure devices or manual compression after failure of closer device attempt. Clopidogrel (300 or 600 mg) or ticlopidine (500 mg) was administered after the procedure in all patients. Patients were thereafter treated with aspirin (100 mg/day indefinitely), and clopidogrel (75 mg/day) or ticlopidine (500 mg/day) for at least 3 months.

End-points and outcome measures {#Sec5}
-------------------------------

The primary safety end-point was the incidence of in-hospital major adverse cardiac events (death from any cause, nonfatal reinfarction, target vessel revascularization and stroke), while the primary efficacy end-point was the incidence of major bleeding complications according to the Acute Catheterization and Urgent Intervention Triage strategY (ACUITY) scale \[[@CR8]\]. Major bleedings were evaluated also according to the Thrombolysis In Myocardial Infarction (TIMI) criteria \[[@CR9]\]. Reinfarction was defined as recurrent chest pain with ST-segment or T-wave changes and recurrent elevation of cardiac enzymes. Stent thrombosis was defined as angiographic documentation of target vessel occlusion or any death or reinfarction that is not clearly related to causes other than stent occlusion. Target vessel revascularization was defined as coronary angioplasty or coronary surgery performed due to restenosis or reocclusion of the infarct artery.

Statistical analysis {#Sec6}
--------------------

Discrete data are summarized as frequencies, while continuous as mean ± SD. Chi-square test analysis was used for comparison of categorical variables. Student *t* test was used to test differences among continuous variables. All analyses were conducted according to the intention-to-treat principle. A *P* value \<0.05 was considered significant. Analyses were performed with SPSS for Windows, version 11.5 (SPSS Inc., Chicago, Illinois).

Results {#Sec7}
=======

The two groups were similar in all baseline clinical and procedural characteristics (Table [1](#Tab1){ref-type="table"}). Femoral access was used in nearly all patients of both groups. Maintenance of anticoagulation after PCI by heparin for at least 12 h in Group 1 occurred in 15 patients (6%) based on operator's decision, while early discontinuation of heparin infusion was observed in 11 patients (4%) of Group 2.Table 1Baseline clinical and procedural characteristicsAbciximab alone (n = 254)Abciximab plus heparin (n = 265)*P* valueAge (years)65 ± 1365 ± 130.963Male185 (72%)198 (75%)0.526Current smoker102 (40%)96 (37%)0.428Hypertension123 (48%)108 (41%)0.137Cholesterolemia \> 200 mg/dl95 (37%)110 (41%)0.267Diabetes mellitus36 (14%)42 (16%)0.511Previous myocardial infarction21 (8%)32 (13%)0.152Anterior infarct location118 (46%)112 (42%)0.379Cardiogenic shock7 (3%)3 (1%)0.179Multivessel disease116 (45%)115 (43%)0.660Preprocedural TIMI grade flow 2--358 (23%)60 (23%)0.599Time of ischemia, min205 ± 124188 ± 1340.138Infarct artery stenting248 (98%)260 (98%)0.481*TIMI* Thrombolysis In Myocardial Infarction

Clinical outcome {#Sec8}
----------------

There were no differences in the incidence of death, myocardial infarction, target vessel revascularization and stroke between groups during hospitalization (Table [2](#Tab2){ref-type="table"}) and at 6 months (Fig. [1](#Fig1){ref-type="fig"}). The cause of in-hospital death was refractory heart failure in most cases of both groups while one death occurred as a consequence of fatal reinfarction in Group 2. In the analysis restricted to high-risk patients, such as those ones with multivessel disease (n = 240), no difference in in-hospital death (4.1 vs. 3.4%, *P* = 0.95) and in acute or subacute stent thrombosis (0.8 vs. 0.8%, *P* = 0.9) was observed between the two groups.Table 2Safety end-pointsAbciximab alone (n = 254)Abciximab plus heparin (n = 265)*P* valueIn-hospital outcomes Death4 (1.6%)4 (1.5%)0.961 Reinfarction2 (0.8%)1 (0.4%)0.538 Target vessel revascularization1 (0.4%)2 (0.8%)0.264Overall MACE^a^6 (2.4%)7 (2.6%)0.839 Stroke2 (0.8%)1 (0.4%)0.538 Acute or subacute stent thrombosis2 (0.8%)1 (0.4%)0.538 Peak CK value (U/L)2466 ± 23312231 ± 21340.232 Time-to-peak CK (h)7.2 ± 6.56.5 ± 3.60.465 Thrombocytopenia (\<100 × 10^9^/l)0 (0%)3 (1%)0.089 Congestive heart failure5 (2.0%)11 (4.1%)0.151Hospitalization length (days)3.4 ± 1.43.9 ± 1.60.0001*CK* creatine kinase^a^*MACE* major adverse cardiac events (death or reinfarction or target vessel revascularization)Fig. 1Six-month clinical outcome of patients receiving postprocedural protamine (Group 1, *black bars*) or 12-h heparin infusion (Group 2, *white bars*)

The incidence of in-hospital major bleeding was more than threefold lower in Group 1 as compared to Group 2 (Table [3](#Tab3){ref-type="table"}). Most of the major bleeding complications occurred at the artery entry site, while fatal bleeding occurred in one patient of Group 2. A trend towards a decreased major bleeding rate was revealed using the more stringent TIMI criteria (0.4 vs. 2.2%, *P* = 0.062). The length of hospital stay was lower in Group 1 as compared to Group 2 (3.5 ± 1.7 vs. 4.0 ± 1.6 days, *P* = 0.002).Table 3Major bleeding complicationsAbciximab alone (n = 254)Abciximab plus heparin (n = 265)*P* valueMajor bleedings (ACUITY scale)3 (1.1%)11 (4.0%)0.035Intracranial bleeding01Access site hemorrage requiring intervention01≥5 cm diameter hematoma03Reduction in hemoglobin concentration of ≥4 g/dl without an overt source of bleeding12Reduction in hemoglobin concentration of ≥3 g/dl with an overt source of bleeding01Use of any blood product transfusion23

Discussion {#Sec9}
==========

The EPIC study results \[[@CR7]\] raised the important question regarding the balance between hemorrhagic risk and clinical benefit with abciximab therapy and standard-dose heparin during PCI. In the EPILOG Trial \[[@CR10]\], abciximab with a reduced-dose heparin treatment showed a lower incidence of major bleeding complications as compared to abciximab with a standard-dose heparin, without affecting the effectiveness of the prevention of PCI ischemic complications. However, bleeding complication after PCI and adjunctive glycoprotein IIb/IIIa inhibition with anticoagulant treatment remains a major issue with significant impact on short and long-term clinical outcomes \[[@CR11]\]. Heparin has shortcomings such as indirect inhibition of antithrombin III, which levels may be quite variable, and it bounds to nonspecific circulating proteins. As a consequence the response to the drug is unpredictable. Recent concluded randomized Trials assessed different antithrombotic strategies in order to reduce the incidence of bleeding without increase in ischemic complications \[[@CR12]--[@CR14]\].

Since the first documentation by Jaques \[[@CR15]\], protamine has been used clinically to promptly reverse the anticoagulant effect of heparin. It must be recognized that protamine is currently largely and safely used after heart surgery, including patients receiving mechanical prosthesis. However, reversal of heparin effect with the administration of protamine may potentially induce hypotension, platelet aggregation, and thrombus formation \[[@CR16]--[@CR18]\]. These fears have refrained from a larger application to promote early sheath removal after PCI.

Several reports have investigated so far the safety of routine application of protamine and early sheath removal after coronary stenting. Pan et al. \[[@CR19]\] randomized 228 patients after successful stent implantation to protamine and in-laboratory sheath removal versus no protamine and delayed sheath removal. No death and in-stent thrombosis were observed in both groups, with shorter hospital stay in patients receiving protamine. In a series of 429 consecutive patients undergoing successful PCI (85% stenting), Ducas et al. \[[@CR20]\] showed that postprocedural protamine administration and early sheath removal was safe with no case of in-laboratory complications and no death at 30-day follow-up, with very low rate of bleeding complications. The safety of protamine administration has been shown by Briguori et al. in 90 patients undergoing coronary stenting \[[@CR21]\].

Thuesen et al. \[[@CR22]\] analyzed the safety and benefits from protamine administration and early sheath removal in a very large cohort of patients undergoing elective PCI between January 1999 and December 2002. There were 1.129 patients (Group 1) admitted between January 1999 to December 1999, with sheath removal 4 h after the PCI procedure, whereas 4.193 patients (Group 2), admitted between January 2000 to December 2002, underwent protamine sulphate administration and early sheath removal. The rates of stent thrombosis, non-fatal myocardial infarction and in-hospital mortality were similar in the two groups. The rate of puncture site complications were significantly lower with protamine and early sheath removal (2.6 vs. 4.7%, *P* \< 0.001). Finally, the safety of heparin reversal by protamine, as compared to the short half-life anticoagulant bivalirudin, has recently been shown in our randomized trial including 850 patients undergoing elective PCI \[[@CR23]\].

Despite the safety of protamine administration largely shown in elective successful stenting, no data have been so far reported in patients with STEMI, where the risk of thrombotic complications may be potentially higher than in elective patients after rapid reversal of heparin.

However, it must be recognized that the HORIZONS trial \[[@CR14]\] has recently demonstrated that anticoagulation therapy after successful primary PCI is no longer needed. In this study more than 3000 STEMI patients undergoing primary angioplasty were randomized to bivalirudin or heparin and glycoprotein IIb-IIIa inhibitors. Since bivalirudin has a 25-min half-life, the risk of thrombotic complications with bivalirudin would have expected to be higher as compared to heparin plus glycoprotein IIb/IIIa inhibitors. However, the slightly higher risk of early (≤24 h) stent thrombosis is explained by the suboptimal inhibition of platelet aggregation as compared to adjunctive administration of glycoprotein IIb--IIIa inhibitors. Remarkably, bivalirudin was associated with a significant reduction in bleeding complications and a lower mortality as compared to heparin plus glycoprotein IIb/IIIa inhibitors.

To the best of our knowledge, this is the first study investigating the potential safety and benefits of protamine administration in patients undergoing primary angioplasty. The results of this study show that post-PCI anticoagulation reversal by protamine and routine abciximab therapy in patients receiving primary infarct artery stenting is not associated with an increase in ischemic complications while the incidence of major bleeding is strongly reduced and the length of in hospital stay significantly shortened. Notably, the incidence of acute and subacute stent thrombosis and of reinfarction was very low in both groups, regardless of protamine administration. The results were confirmed in high-risk patients, such as those with multivessel disease.

Thus, the results of our study are consistent with those in elective patients and exclude the hypothesis of a rebound pro-thrombotic state after immediate heparin neutralization due to heparin activated platelets or a heparin rebound with reappearance of anticoagulant activity after protamine administration.

Future randomized trials are certainly needed to investigate whether bivalirudin is still superior in terms of mortality as compared to a strategy of heparin, abciximab and early postprocedural sheath removal pending protamine administration, in patients undergoing primary PCI for STEMI in the era of new generation antiplatelets agents \[[@CR24]--[@CR25]\].

Study limitations {#Sec10}
=================

Our results must be evaluated in the light of some study limitations. This was a nonrandomized study. However, only unselected and consecutive patients were enrolled, and the two study groups were similar in baseline characteristics. The shorter length of hospital stay of the more recent group might be, at least in part, due to the fact that the length of hospital stay for STEMI has decreased worldwide in recent years. However, we adopted an early discharge strategy before the beginning of study enrolment and post-procedure heparin infusion was related to the hospital stay length. The relatively small size may have affected the results and made the study underpowered to evaluate a strong endpoint, such as mortality. Postprocedural Heparin infusion is not recommended anymore, and it might have favoured the benefits observed in our study in terms of bleeding complications with protamine administration. A propensity score analysis was not performed, being the groups homogeneous with no difference in baseline characteristics, except than of Heparin infusion (as per protocol).

Conclusions {#Sec11}
===========

The strategy of routine immediate reversal of anticoagulation state after primary infarct artery stenting for STEMI with routine abciximab as adjunctive therapy seems safe and associated with a strong reduction in major bleeding complications and with a shorter hospital stay. Thus, our study, confirming recent findings of the HORIZONS trial, suggest that prolonged blood anticoagulation is not longer needed after primary PCI, especially with adjunctive use of glycoprotein IIb--IIIa inhibitors. However, future randomized trials are certainly needed to confirm our findings and to compare this strategy to the use of bivalirudin in the era of new antiplatelet compounds.
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